As India presented the Union Budget 2026, market participants approached the policy event with a measured mix of caution and ...

The India formulations business continued to perform well, with revenue increasing 22% year on year to ₹1,298.6 crore ...

The policy move is likely to reduce compliance requirements and lower transaction costs associated with overseas investments ...

Union Finance Minister Nirmala Sitharaman announced a major new initiative in the Union Budget 2026, with the central government planning to launch the Bio Pharma Shakti scheme with an outlay of ...

The company reported exceptional items amounting to ₹21.2 crore during the quarter, linked to the implementation of the new ...

Consolidated net debt stood at ₹15,443 crore at the end of the December quarter, higher than ₹14,156 crore reported as of ...

Revenue for the quarter rose 2.8% to ₹1,004 crore, reflecting steady demand across core brands amid a competitive operating ...

Indian investors not only want a better investing environment, but also more investment options to choose from ...

A very high ratio of fiscal deficit to GDP has several negative implications. For starters, it tends to weaken the rupee and ...

While large scale changes in tax rates are unlikely, the markets will look at some smart tweaking of tax rates ...

Revenue for the quarter declined by 3.5% on a sequential basis to ₹731.3 crore, compared with ₹758 crore recorded in the previous quarter ...

Revenue from operations grew 15.7% year on year to ₹1,806 crore during the quarter, up from ₹1,561.4 crore in Q3 FY25 ...